{"result": {"id": "fd0f04af-7826-440c-929e-53904da8770b", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ARTERIOSCLEROSIS<|>EVENT<|>A disease characterized by the hardening of the arteries, often requiring statin-based lipid-lowering drugs for treatment\")\n##\n(\"entity\"<|>STATINS<|>ORGANIZATION<|>A class of lipid-lowering drugs recommended as the first choice for patients with arteriosclerosis and certain high-risk groups\")\n##\n(\"entity\"<|>NIACIN<|>ORGANIZATION<|>A type of lipid-lowering drug considered as an alternative to statins for specific patient groups\")\n##\n(\"entity\"<|>RESINS<|>ORGANIZATION<|>The only safe lipid-lowering drugs during pregnancy\")\n##\n(\"entity\"<|>LOVASTATIN<|>ORGANIZATION<|>A statin drug with potential adverse effects including headache, gastrointestinal issues, and liver abnormalities\")\n##\n(\"entity\"<|>SIMVASTATIN<|>ORGANIZATION<|>A statin drug that may cause muscle pain, liver abnormalities, and other side effects\")\n##\n(\"entity\"<|>PRAVASTATIN<|>ORGANIZATION<|>A statin drug associated with various adverse effects including liver damage and muscle issues\")\n##\n(\"entity\"<|>CLOFIBRATE<|>ORGANIZATION<|>A lipid-lowering drug with specific contraindications and side effects\")\n##\n(\"relationship\"<|>ARTERIOSCLEROSIS<|>STATINS<|>Statin drugs are the first-line treatment for arteriosclerosis<|>8\")\n##\n(\"relationship\"<|>STATINS<|>NIACIN<|>Both are lipid-lowering drugs used for specific patient groups<|>6\")\n##\n(\"relationship\"<|>STATINS<|>RESINS<|>Different classes of lipid-lowering drugs with specific use cases<|>4\")\n##\n(\"relationship\"<|>LOVASTATIN<|>SIMVASTATIN<|>Both are statin drugs with similar side effect profiles<|>7\")\n##\n(\"relationship\"<|>LOVASTATIN<|>PRAVASTATIN<|>Both are statin drugs with overlapping adverse effects<|>7\")\n##\n(\"relationship\"<|>SIMVASTATIN<|>PRAVASTATIN<|>Both are statin drugs requiring liver function monitoring<|>7\")\n##\n(\"relationship\"<|>LOVASTATIN<|>CLOFIBRATE<|>Both are lipid-lowering drugs with different mechanisms and side effects<|>5\")\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166205, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 558, "prompt_tokens": 2403, "total_tokens": 2961, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 611}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �内成形术的需要。\n　　　已确诊为动脉硬化病的病人应首选他汀类降脂药。还无动脉 硬化病的高脂血症病人，在选择降脂药时应区别对待：源缘～远源岁 的男性病人，应首选他汀类降脂药；猿缘～源岁、远缘～苑缘岁的男性病 人及绝经后的女性病人，他汀类或烟酸类降脂药均可考虑；绝经前 女性极少需要降脂治疗；妊娠期间，树脂类药物是惟一安全的降 脂药。\n　　　随着国人生活水平的日益提高，高脂血症的发病率有明显上 升趋势，降低血脂已经成了与千家万户息息相关、迫在眉睫的事 情，必须全民行动起来，打一场降低血脂的“持久战”。\n摇摇源猿援降血脂药的不良反应及禁忌\n　　（员）洛伐他汀（美降脂、乐瓦停、脉温宁）摇 ①不良反应有头 痛、倦怠、胃肠道反应、皮疹、白细胞和血小板减少、肝功能异常、周 围神经病变等；②儿童、孕妇、哺乳期妇女及对该药过敏者禁用，少 数病人转氨酶明显升高，大量饮酒和有肝病史者慎用；③与免疫抑 制剂、吉非贝齐和烟酸合用可引起肌病，甚至发生横纹肌溶解，应\n圆                                                    \n\n\n\n\n\t 六、高脂血症的治疗         \n特别慎重；④与抗凝剂合用，偶见有凝血酶原时间延长和出血。\n（圆）辛伐他汀（新伐他汀、斯伐他汀、塞瓦停、舒降之、舒降脂）\n摇①不良反应有肌酸磷酸激酶（悦孕运）一过性增高、肝功能异常、肌 痛、肌无力等；②肝病、磷酸肌酸激酶升高或诊断有肌病者、孕妇禁 用，有肝病史及大量饮酒者慎用；③用药期间应定期检查肝功能。\n　　（猿）普伐他汀（普拉司汀、帕伐他汀、普拉固、帕瓦停、萘维太  定、美百乐镇）摇 ①不良反应可有头痛、倦怠、胃肠道反应、皮疹、 白细胞和血小板减少、肝功能异常、周围神经病变、肌酸磷酸激酶 升高、尿酸升高及尿隐血等； ②肝病、孕妇及哺乳期妇女禁用，有肝 病史或饮酒史者慎用；③对肝脏有损害，用药期间定期检查肝功 能；④如有不明原因的肌痛、触痛、无力，特别是伴有不适和发热 者，应特别注意。\n　　（源）氯贝特（氯贝丁酯、氯苯\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_a20f75c257606d5c590df3fc75c610f560ace0e7f7c32156154b0426bfbb5ac1_v2"}